Key result
The ratio of cardiac myosin-binding protein C to cardiac troponin I in type 1 MI was highest at presentation and decreased over time.
Why the study?
Early triage of patients with acute myocardial infarction is limited by the slow release of cardiac troponins, necessitating repeat testing and causing delays in treatment.
Answers are grounded in this paper and cite their sources.
Cardiac myosin-binding protein C (cMyC) rises more rapidly than cardiac troponin I in early type 1 myocardial infarction, suggesting potential utility for more rapid triage of acute chest pain.
To the Editor: Although acute chest pain is a common presenting symptom, the proportion of patients with acute myocardial infarction (AMI)1 who have diagnostic electrocardiographic changes on presentation is dwindling. Consequently, early triage of chest pain patients is becoming ever more reliant on assessment of the release of cardiac troponin I (cTnI) or cTnT into the systemic circulation. However, these biomarkers are released relatively slowly, reaching their peak many hours after symptom onset (1). To achieve rapid triage, the latest guidelines recommend the use of assays for cTnI and cTnT that have very high analytical sensitivity to rule-in and rule-out AMI based on concentrations markedly above and markedly below the population-defined 99th percentiles, respectively. The use of these widely spaced decision limits improves the specificity of rule-in and the sensitivity of rule-out. However, the majority of patients presenting with chest pain have cardiac troponin concentrations that place them between these decision limits, in an indeterminate zone. These patients require repeat testing and subsequent second or third rounds of triage based on rates of change of cardiac troponin concentration over time (2). This introduces systematic delays in allocation of evidence-based treatments and prolongs stay in the pressured and precious environment of the emergency department. We have described a new biomarker of cardiac injury—cardiac myosin-binding protein C (cMyC)—which rises more rapidly in the systemic circulation than cTnT after iatrogenic myocardial infarction in the cardiac catheterization laboratory (3). The purpose of the study we describe here was to determine if the temporal differences between cMyC and cardiac troponin observed in the catheter laboratory could extend to patients presenting with symptoms of short duration because of spontaneous coronary atherosclerotic plaque rupture (type 1 AMI). We identified 174 patients from the High-STEACS (High-Sensitivity Troponin in the Evaluation of Patients with Acute Coronary Syndrome) cohort (4) with symptoms of <3 h duration before the first blood draw (0 h) and with serum/plasma available at 3 h (early) and at 6–12 h (late) after presentation. Of these 174 patients, 26 were adjudicated as having type 1 myocardial infarction [see (4) for further details]. To determine if the concentration trends for cMyC over time differ from those of cTnI, we calculated the ratio of cMyC to cTnI (cMyC and cTnI both expressed as ng/L) at each of the 3 blood sampling time points. cTnI was measured using the Abbot ARCHITECTSTAT high-sensitive troponin I assay [Abbott Laboratories; limit of detection of 1.2 ng/L, upper reference limit (99th centile) of 34 ng/L in men and 16 ng/L in women]. cMyC was measured using a high-sensitivity assay performed by Singulex on the Erenna platform using our proprietary reagents as recently described [limit of detection of 0.4 ng/L, upper reference limit (99th percentile) approximately 80 ng/L] (5). The demographics of our study population presenting early with type 1 AMI are similar to those of the parent cohort (age 68.8 years, women 23.1%, primary symptom chest pain 84.6%, previous percutaneous coronary intervention 15.4%). At each of the 3 time points we found a strong linear correlation between cMyC and cTnI, as we previously observed in an ambulatory population (5): Spearman ρ 0.795 (P < 0.01) at presentation, 0.902 (P < 0.01) at 3 h, and 0.888 (P < 0.01) at the late time point. Nonetheless, the ratio of cMyC to cTnI was the highest at presentation, thereafter decreasing significantly with time from presentation, mean ratio at presentation, 7.98 [median, 2.72; interquartile range (IQR), 3.48]; at 3 h, 2.67 (median, 1.83; IQR, 1.40); and at the late time point, 1.71 (median, 0.63; IQR, 1.09)—all P < 0.01 by Friedman 2-way ANOVA by ranks. Furthermore, the ratio was also significantly greater than that we observed previously in a stable cohort without obstructive coronary artery disease and with a cTnT <14 ng/L (mean 1.97) (5). Although the mean ratio of cMyC:cTnI was highest at presentation, there was substantial individual heterogeneity among the 26 patients with type 1 AMI (Fig. 1). The relative concentration of cMyC to cTnI at presentation soon after symptom onset in those with type 1 AMI was higher than in the same patients at later time points and in ambulatory patients at low risk. The more rapid rise of cMyC vs cTnI that we have observed in patients with type 1 AMI should enable their more rapid/accurate triage. However, the diagnostic performance of cMyC, with and without cTnI, needs further evaluation. Patient 7, with no previous cardiovascular disease history but with 1-h atypical chest pain without electrocardiographic changes, died suddenly before cardiac investigation. Patient 8, known extensive cardiovascular disease, diffuse ischemic heart disease on angiography without target, managed conservatively. Patient 10, renal replacement therapy with extensive cardiovascular disease history, 1-h severe typical chest pain, managed conservatively. NA, no coronary angiography performed; M, cMyC 99th percentile (80 ng/L); T, cTnI 99th percentile (sex-specific, 34 ng/L in men; 16 ng/L in women); PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; AVR, aortic valve replacement; IP, inpatient; LAD, left anterior descending; Cx, circumflex; RCA, right coronary artery. acute myocardial infarction cardiac troponin I cardiac myosin-binding protein C interquartile range. The study was approved by the national research ethics committee, and in accordance with the Declaration of Helsinki.
No takes yet. Share an insight, caveat, or question.
Kaier et al. (2016) conducted a letter in Type 1 Myocardial Infarction (n=26). Cardiac myosin-binding protein C (cMyC) vs. Cardiac troponin I (cTnI) was evaluated on Ratio of cMyC to cTnI over time (p=<0.01). The ratio of cardiac myosin-binding protein C to cardiac troponin I in type 1 MI was highest at presentation and decreased over time.
Synapse has enriched 10 related papers. Consider them for comparative context: